Status:
RECRUITING
Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Heart Failure
Diabetes
Eligibility:
All Genders
Phase:
NA
Brief Summary
A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies...
Detailed Description
Historic echocardiograms will be analyzed using the Ultromics EchoGo algorithm. For patients that have a positive EchoGO result i.e. HFpEF detected, the provider will get an clinical decision support ...
Eligibility Criteria
Inclusion
- Clinical cohort inclusion exclusion criteria:
- Patients with diagnosis of Type 2 diabetes and High WATCH DM score.
- Echocardiogram available in last 6-months.
Exclusion
- History of HF
- Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA
- Corresponding providers to patients identified by the above inclusion exclusion criteria will be included in the clinical trial of the decision support tool.
Key Trial Info
Start Date :
August 6 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 15 2027
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT06593314
Start Date
August 6 2025
End Date
June 15 2027
Last Update
August 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT Southwestern Medical Center
Dallas, Texas, United States, 75235